DANAHER CORP DHR 65.95
Technology · NYSE · Data as of 2026-10-21
DANAHER CORP (DHR) has delivered +4.6% annualized revenue growth, +7.8% earnings growth, and +10.7% dividend growth over 10 years of data. Ranked #369 of 1968 stocks overall and #49 of 362 in the Technology sector by Steady Score.
About DANAHER CORP
Company Overview
Danaher provides instruments, consumables and services for life-science research, biotechnology production and clinical diagnostics. Its businesses supply microscopy, mass spectrometry, filtration, chromatography, genomic tools and laboratory analyzers. Pharmaceutical companies, researchers and hospitals use these products to discover and manufacture therapies and diagnose disease. The company operates through established scientific brands across global markets.
Read more
Business Model & Revenue
Revenue comes from instruments and equipment plus recurring reagents, consumables, software and service. Biotechnology, Life Sciences and Diagnostics serve different stages of research, production and clinical testing. Installed systems generate repeat demand, while large instruments depend on capital budgets. Biopharma research, production volumes, diagnostic testing and acquisitions drive sales; the Danaher Business System guides operating improvement.
Key Facts & Market Position
Danaher reshaped its portfolio through acquisitions and the separation of businesses such as Veralto, concentrating on health and life sciences. Many workflows require validated consumables and reliable service, supporting ongoing customer relationships. Research funding, biotech cycles, regulatory quality and successful integration of large acquired platforms remain material.